Problem
Increasing drug experimentation in developing countries
Nature:
Introduction of experimental pharmaceuticals into less developed countries where public health regulations are not restrictive, is an increasing phenomenon.
Incidence:
Trials of new contraceptive drugs, for example, are often conducted in Third World countries which may have no preclinical requirements or supervision for therapeutic testing; pharmaceutical companies may wish to evade controls imposed for the safety of women's health in such trials. Drug companies in the USA, for example, spend between 15 and 20% of their research budgets abroad, mainly in developing countries, for all kinds of products.
Broader Problems:
Unproven new methodsUnethical experiments with drugs and medical devices Subject(s):
Health Care → PharmacyResearch, Standards → Experimental
Related UN Sustainable Development Goals:
Problem Type:
E: Emanations of other problems Date of last update
04.10.2020 – 22:48 CEST